Phoenix Financial Ltd. Purchases 564 Shares of Gilead Sciences, Inc. $GILD

Phoenix Financial Ltd. boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 5.9% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 10,094 shares of the biopharmaceutical company’s stock after acquiring an additional 564 shares during the period. Phoenix Financial Ltd.’s holdings in Gilead Sciences were worth $1,119,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Southland Equity Partners LLC raised its stake in Gilead Sciences by 2.9% in the 2nd quarter. Southland Equity Partners LLC now owns 3,285 shares of the biopharmaceutical company’s stock valued at $364,000 after acquiring an additional 92 shares during the period. Twelve Points Wealth Management LLC raised its stake in Gilead Sciences by 1.5% in the 2nd quarter. Twelve Points Wealth Management LLC now owns 6,499 shares of the biopharmaceutical company’s stock valued at $721,000 after acquiring an additional 98 shares during the period. Argentarii LLC raised its stake in Gilead Sciences by 3.0% in the 1st quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company’s stock valued at $380,000 after acquiring an additional 99 shares during the period. Lodestar Private Asset Management LLC raised its stake in Gilead Sciences by 3.6% in the 1st quarter. Lodestar Private Asset Management LLC now owns 2,840 shares of the biopharmaceutical company’s stock valued at $318,000 after acquiring an additional 100 shares during the period. Finally, RDA Financial Network grew its holdings in Gilead Sciences by 5.1% during the 2nd quarter. RDA Financial Network now owns 2,129 shares of the biopharmaceutical company’s stock valued at $236,000 after buying an additional 103 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on GILD shares. UBS Group lifted their target price on Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a report on Friday, August 8th. The Goldman Sachs Group lifted their target price on Gilead Sciences from $105.00 to $108.00 and gave the company a “neutral” rating in a report on Friday, October 17th. Dbs Bank raised Gilead Sciences to a “moderate buy” rating in a report on Friday, September 5th. Daiwa Capital Markets raised Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 target price for the company in a report on Tuesday, August 19th. Finally, Cantor Fitzgerald lifted their target price on Gilead Sciences from $129.00 to $135.00 and gave the company an “overweight” rating in a report on Thursday, October 9th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and a consensus price target of $121.14.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total value of $295,200.00. Following the completion of the sale, the chief financial officer owned 157,055 shares in the company, valued at $18,545,054.40. The trade was a 1.57% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $111.66, for a total value of $1,116,600.00. Following the completion of the sale, the chief executive officer owned 591,203 shares of the company’s stock, valued at $66,013,726.98. The trade was a 1.66% decrease in their position. The disclosure for this sale can be found here. Insiders sold 71,500 shares of company stock worth $8,281,540 in the last quarter. 0.27% of the stock is owned by insiders.

Gilead Sciences Stock Up 0.8%

Shares of NASDAQ GILD opened at $124.08 on Wednesday. Gilead Sciences, Inc. has a 12 month low of $85.60 and a 12 month high of $124.61. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The firm has a market capitalization of $153.96 billion, a price-to-earnings ratio of 24.72, a PEG ratio of 0.84 and a beta of 0.34. The business has a 50-day moving average of $115.35 and a 200-day moving average of $110.71.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. During the same quarter in the previous year, the firm earned $2.01 earnings per share. Gilead Sciences’s revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were given a $0.79 dividend. The ex-dividend date was Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.5%. Gilead Sciences’s payout ratio is presently 62.95%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.